Suppr超能文献

[人甲状腺肿瘤中表皮生长因子受体和雌激素受体的免疫组织化学研究]

[Immunohistochemical study of epidermal growth factor receptor and estrogen receptor in human thyroid tumors].

作者信息

Yane K, Tanaka O, Miyahara H, Matsunaga T, Kitahori Y, Hiasa Y

机构信息

Department of Otorhinolaryngology, Nara Medical University.

出版信息

Nihon Jibiinkoka Gakkai Kaiho. 1993 May;96(5):787-90. doi: 10.3950/jibiinkoka.96.787.

Abstract

Expressions of epidermal growth factor receptor (EGFR) and estrogen receptor (ER) in human thyroid tumors were examined immunohistochemically in frozen sections. Forty-eight fresh surgical specimens of thyroid tissues, 19 carcinomas, 12 adenomas, 7 adenomatous goiters and 10 normal thyroid tissues were studied. All cases, including normal thyroid tissues, expressed the EGFR immunoreaction in the cytoplasm. Incidences of stronger than (+) staining intensity of EGFR were 84% (16/19) in carcinoma, 67% (8/12) in adenoma, 57% (4/7) in adenomatous goiter and 30% (3/10) in normal thyroid tissue. This result suggests that the staining intensity of EGFR expression is associated with malignant potential. The frequency of ER positive cases was 11% (2/19) in carcinoma, 17% (2/12) in adenoma and 0% in both adenomatous goiter and normal thyroid tissue. No relationship between EGFR and ER expression was recognized. However, a case of papillary carcinoma with strong ER immunoreactive intensity expressed weak EGFR intensity, suggesting an inverse relation in immunoreaction between EGFR and ER in papillary carcinoma.

摘要

采用免疫组织化学方法对人甲状腺肿瘤冰冻切片中表皮生长因子受体(EGFR)和雌激素受体(ER)的表达进行检测。研究了48例新鲜手术切除的甲状腺组织标本,其中19例为癌组织,12例为腺瘤,7例为腺瘤性甲状腺肿,10例为正常甲状腺组织。所有病例,包括正常甲状腺组织,在细胞质中均表达EGFR免疫反应。EGFR染色强度强于(+)的发生率在癌组织中为84%(16/19),腺瘤中为67%(8/12),腺瘤性甲状腺肿中为57%(4/7),正常甲状腺组织中为30%(3/10)。这一结果提示EGFR表达的染色强度与恶性潜能相关。ER阳性病例的频率在癌组织中为11%(2/19),腺瘤中为17%(2/12),腺瘤性甲状腺肿和正常甲状腺组织中均为0%。未发现EGFR与ER表达之间存在相关性。然而,1例ER免疫反应强度强的乳头状癌病例EGFR强度较弱,提示乳头状癌中EGFR与ER免疫反应呈负相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验